David J Park* and Steven D Chang
Volume5-Issue6
Dates: Received: 2024-06-07 | Accepted: 2024-06-08 | Published: 2024-06-08
Pages: 537-539
Abstract
Gliomas, particularly high-grade gliomas like glioblastomas, represent some of the most formidable challenges in oncology. These brain tumors are notorious for their resistance to conventional therapies, including surgery, chemotherapy, and radiation. The recent systematic review and meta-analysis protocol offers a promising direction by focusing on Tumor Mutation Burden (TMB) and Tumor Microenvironment (TME) as potential biomarkers for treatment outcomes and prognosis in gliomas.
FullText HTML
FullText PDF
DOI: 10.37871/jbres1923
Certificate of Publication
Copyright
© 2024 Park DJ, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Park DJ, Chang SD. The Promise of Tumor Mutation Burden and Microenvironment as Biomarkers in Glioma Treatment. J Biomed Res Environ Sci. 2024 Jun 08; 5(6): 537-539. doi: 10.37871/jbres1923, Article ID: JBRES1923, Available at: https:// www.jelsciences.com/articles/jbres1923.pdf
Subject area(s)
References
- Ahmad H, Fadul CE, Schiff D, Purow B. Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas. Neurooncol Pract. 2019 Dec;6(6):424-427. doi: 10.1093/nop/npz016. Epub 2019 Apr 7. PMID: 31832212; PMCID: PMC6899050.
- Yu G, Pang Y, Merchant M, Kesserwan C, Gangalapudi V, Abdelmaksoud A, Ranjan A, Kim O, Wei JS, Chou HC, Wen X, Sindiri S, Song YK, Xi L, Kaplan RN, Armstrong TS, Gilbert MR, Aldape K, Khan J, Wu J. Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers (Basel). 2021 Dec 3;13(23):6092. doi: 10.3390/cancers13236092. PMID: 34885201; PMCID: PMC8657099.
- Kang K, Xie F, Wu Y, Wang Z, Wang L, Long J, Lian X, Zhang F. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. Int Immunopharmacol. 2021 Jul;96:107610. doi: 10.1016/j.intimp.2021.107610. Epub 2021 Apr 10. PMID: 33848908.
- Strickler JH, Hanks BA, Khasraw M. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? Clin Cancer Res. 2021 Mar 1;27(5):1236-1241. doi: 10.1158/1078-0432.CCR-20-3054. Epub 2020 Nov 16. PMID: 33199494; PMCID: PMC9912042.
- Alghamri MS, Thalla R, Avvari RP, Dabaja A, Taher A, Zhao L, Ulintz PJ, Castro MG, Lowenstein PR. Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. Neurooncol Adv. 2020 Mar 27;2(1):vdaa042. doi: 10.1093/noajnl/vdaa042. PMID: 32642696; PMCID: PMC7212865.
- Su J, Long W, Ma Q, Xiao K, Li Y, Xiao Q, Peng G, Yuan J, Liu Q. Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas. Front Genet. 2019 Nov 15;10:1143. doi: 10.3389/fgene.2019.01143. PMID: 31803233; PMCID: PMC6872675.
- Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, Kurc T, Van Meir EG, Saltz JH, Moreno CS, Brat DJ. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. 2012 May;180(5):2108-19. doi: 10.1016/j.ajpath.2012.01.040. Epub 2012 Mar 20. PMID: 22440258; PMCID: PMC3354586.
- Shen M, Kang Y. Complex interplay between tumor microenvironment and cancer therapy. Front Med. 2018 Aug;12(4):426-439. doi: 10.1007/s11684-018-0663-7. Epub 2018 Aug 10. PMID: 30097962.
- Wang L, Ge J, Lan Y, Shi Y, Luo Y, Tan Y, Liang M, Deng S, Zhang X, Wang W, Tan Y, Xu Y, Luo T. Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer. 2020 Mar 12;20(1):213. doi: 10.1186/s12885-020-6658-1. PMID: 32164609; PMCID: PMC7069200.
